Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination

1.

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

2.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

3.

Buy, J. N., Moss, A. A., Ghossain, M. A., Sciot, C., Malbec, L., Vadrot, D., … Decroix, Y. (1988). Peritoneal implants from ovarian tumors: CT findings. Radiology, 169(3), 691–694. https://doi.org/10.1148/radiology.169.3.3186993

4.

Arie, A. B., McNally, L., Kapp, D. S., & Teng, N. N. H. (2013). The omentum and omentectomy in epithelial ovarian cancer: A reappraisal: Part II—The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecologic oncology, 131(3), 784–790. https://doi.org/10.1016/j.ygyno.2013.09.013CrossRefPubMed

5.

Ben Arie, A., McNally, L., Kapp, D. S., & Teng, N. N. H. (2013). The omentum and omentectomy in epithelial ovarian cancer: A reappraisal. Part I—Omental function and history of omentectomy. Gynecologic oncology, 131(3), 780–783. https://doi.org/10.1016/j.ygyno.2013.09.014CrossRefPubMed

6.

Heintz, A. P. M., Odicino, F., Maisonneuve, P., Quinn, M. A., Benedet, J. L., Creasman, W. T., … Beller, U. (2006). Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 95 Suppl 1, S161–92. https://doi.org/10.1016/S0020-7292(06)60033-7

7.

Amate, P., Huchon, C., Dessapt, A. L., Bensaid, C., Medioni, J., Le Frère Belda, M.-A., … Lécuru, F. R. (2013). Ovarian cancer: Sites of recurrence. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 23(9), 1590–1596. https://doi.org/10.1097/IGC.0000000000000007

8.

Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., … Reeves, G. K. (2022). Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer epidemiology, 76(102074), 102074. https://doi.org/10.1016/j.canep.2021.102074

9.

Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615. https://doi.org/10.1038/nature10166CrossRef

10.

Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., … Bowtell, D. D. L. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research, 14(16), 5198–5208. https://doi.org/10.1158/1078-0432.CCR-08-0196

11.

Vargas, H. A., Miccò, M., Hong, S. I., Goldman, D. A., Dao, F., Weigelt, B., … Sala, E. (2015). Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology, 274(3), 742–751. https://doi.org/10.1148/radiol.14141477

12.

Zhang, Q., Wang, C., & Cliby, W. A. (2019). Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecologic Oncology, 152(2), 368–374. https://doi.org/10.1016/j.ygyno.2018.11.014CrossRefPubMed

13.

Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., … Liu, L. (2019). The role of collagen in cancer: from bench to bedside. Journal of Translational Medicine, 17(1), 309. https://doi.org/10.1186/s12967-019-2058-1

14.

Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014). The wound healing, chronic fibrosis, and cancer progression triad. Physiological Genomics, 46(7), 223–244. https://doi.org/10.1152/physiolgenomics.00158.2013CrossRefPubMedPubMedCentral

15.

Byun, J. S., & Gardner, K. (2013). Wounds that will not heal: Pervasive cellular reprogramming in cancer. The American Journal of Pathology, 182(4), 1055–1064. https://doi.org/10.1016/j.ajpath.2013.01.009CrossRefPubMedPubMedCentral

16.

Sundaram, G. M., Quah, S., & Sampath, P. (2018). Cancer: The dark side of wound healing. The FEBS Journal, 285(24), 4516–4534. https://doi.org/10.1111/febs.14586CrossRefPubMed

17.

MacCarthy-Morrogh, L., & Martin, P. (2020). The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling, 13(648), eaay8690. https://doi.org/10.1126/scisignal.aay8690CrossRefPubMed

18.

Haddow, A. (1972). Molecular repair, wound healing, and carcinogenesis: Tumor production a possible overhealing? Advances in Cancer Research, 16, 181–234. https://doi.org/10.1016/s0065-230x(08)60341-3CrossRefPubMed

19.

Schäfer, M., & Werner, S. (2008). Cancer as an overhealing wound: An old hypothesis revisited. Nature reviews. Molecular Cell Biology, 9(8), 628–638. https://doi.org/10.1038/nrm2455CrossRefPubMed

20.

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a glance. Journal of Cell Science, 125(Pt 23), 5591–5596. https://doi.org/10.1242/jcs.116392CrossRefPubMed

21.

Huet, E., Jaroz, C., Nguyen, H. Q., Belkacemi, Y., de la Taille, A., Stavrinides, V., & Whitaker, H. (2019). Stroma in normal and cancer wound healing. The FEBS Journal, 286(15), 2909–2920. https://doi.org/10.1111/febs.14842CrossRefPubMed

22.

Erdogan, B., & Webb, D. J. (2017). Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochemical Society Transactions, 45(1), 229–236. https://doi.org/10.1042/bst20160387CrossRefPubMedPubMedCentral

23.

Ricciardelli, C., & Rodgers, R. J. (2006). Extracellular matrix of ovarian tumors. Seminars in Reproductive Medicine, 24(4), 270–282. https://doi.org/10.1055/s-2006-948556CrossRefPubMed

24.

Lu, P., Takai, K., Weaver, V. M., & Werb, Z. (2011). Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harbor Perspectives in Biology, 3(12), a005058–a005058. https://doi.org/10.1101/cshperspect.a005058CrossRefPubMedPubMedCentral

25.

Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/10.1016/j.cell.2010.03.015CrossRefPubMedPubMedCentral

26.

Carey, P., Low, E., Harper, E., & Stack, M. S. (2021). Metalloproteinases in ovarian cancer. International Journal of Molecular Sciences, 22(7), 3403. https://doi.org/10.3390/ijms22073403CrossRefPubMedPubMedCentral

27.

Al-Alem, L., & Curry, T. E., Jr. (2015). Ovarian cancer: Involvement of the matrix metalloproteinases. Reproduction, 150(2), R55-64. https://doi.org/10.1530/REP-14-0546CrossRefPubMedPubMedCentral

28.

Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., & Giavazzi, R. (2003). Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer research, 63(17), 5224–5229. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14500349. Accessed 22 Aug 2023

29.

Mott, J. D., & Werb, Z. (2004). Regulation of matrix biology by matrix metalloproteinases. Current Opinion in Cell Biology, 16(5), 558–564. https://doi.org/10.1016/j.ceb.2004.07.010CrossRefPubMedPubMedCentral

30.

Yu, Q., & Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes & Development, 14(2), 163–176. https://doi.org/10.1101/gad.14.2.163CrossRef

31.

Cai, L., Xiong, X., Kong, X., & Xie, J. (2017). The role of the lysyl oxidases in tissue repair and remodeling: A concise review. Tissue Engineering and Regenerative Medicine, 14(1), 15–30. https://doi.org/10.1007/s13770-016-0007-0CrossRefPubMedPubMedCentral

32.

Setargew, Y. F. I., Wyllie, K., Grant, R. D., Chitty, J. L., & Cox, T. R. (2021). Targeting lysyl oxidase family meditated matrix cross-linking as an anti-stromal therapy in solid tumours. Cancers, 13(3), 491. https://doi.org/10.3390/cancers13030491CrossRefPubMedPubMedCentral

33.

De Donato, M., Petrillo, M., Martinelli, E., Filippetti, F., Zannoni, G. F., Scambia, G., & Gallo, D. (2017). Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer. Gynecologic Oncology, 146(1), 170–178. https://doi.org/10.1016/j.ygyno.2017.05.001CrossRefPubMed

34.

Ji, F., Wang, Y., Qiu, L., Li, S., Zhu, J., Liang, Z., … Di, W. (2013). Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. International Journal of Oncology, 42(5), 1578–1588. https://doi.org/10.3892/ijo.2013.1878

35.

Wang, Y., Ma, J., Shen, H., Wang, C., Sun, Y., Howell, S. B., & Lin, X. (2014). Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncology Reports, 32(5), 2150–2158. https://doi.org/10.3892/or.2014.3448CrossRefPubMedPubMedCentral

36.

Ye, M., Zhou, J., Gao, Y., Pan, S., & Zhu, X. (2020). The prognostic value of the lysyl oxidase family in ovarian cancer. Journal of Clinical Laboratory Analysis, 34(12), e23538. https://doi.org/10.1002/jcla.23538CrossRefPubMedPubMedCentral

37.

Ishihara, S., & Haga, H. (2022). Matrix stiffness contributes to cancer progression by regulating transcription factors. Cancers, 14(4), 1049. https://doi.org/10.3390/cancers14041049CrossRefPubMedPubMedCentral

38.

Ouellette, J. N., Drifka, C. R., Pointer, K. B., Liu, Y., Lieberthal, T. J., Kao, W. J., … Eliceiri, K. W. (2021). Navigating the collagen jungle: The biomedical potential of fiber organization in cancer. Bioengineering (Basel, Switzerland), 8(2), 17. https://doi.org/10.3390/bioengineering8020017

39.

Ricard-Blum, S. (2011). The collagen family. Cold Spring Harbor Perspectives in Biology, 3(1), a004978. https://doi.org/10.1101/cshperspect.a004978CrossRefPubMedPubMedCentral

40.

Sarwar, M., Sykes, P. H., Chitcholtan, K., & Evans, J. J. (2022). Collagen I dysregulation is pivotal for ovarian cancer progression. Tissue & cell, 74(101704), 101704. https://doi.org/10.1016/j.tice.2021.101704CrossRef

41.

Liu, M., Zhang, X., Long, C., Xu, H., Cheng, X., Chang, J., … Wang, X. (2018). Collagen-based three-dimensional culture microenvironment promotes epithelial to mesenchymal transition and drug resistance of human ovarian cancer in vitro. RSC Advances, 8(16), 8910–8919. https://doi.org/10.1039/c7ra13742g

42.

Wang, M., Wang, J., Liu, J., Zhu, L., Ma, H., Zou, J., … Wang, K. (2020). Systematic prediction of key genes for ovarian cancer by co-expression network analysis. Journal of Cellular and Molecular Medicine, 24(11), 6298–6307. https://doi.org/10.1111/jcmm.15271

43.

Ganapathi, M. K., Jones, W. D., Sehouli, J., Michener, C. M., Braicu, I. E., Norris, E. J., … Ganapathi, R. N. (2016). Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer. International journal of cancer. Journal International du Cancer, 138(3), 679–688. https://doi.org/10.1002/ijc.29815

44.

Clarke, C. J., Berg, T. J., Birch, J., Ennis, D., Mitchell, L., Cloix, C., … Norman, J. C. (2016). The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology: CB, 26(6), 755–765. https://doi.org/10.1016/j.cub.2016.01.045

45.

Kenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007). Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. International journal of cancer. Journal International du Cancer, 121(7), 1463–1472. https://doi.org/10.1002/ijc.22874

46.

Bar, J. K., Grelewski, P., Popiela, A., Noga, L., & Rabczyñski, J. (2004). Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: Correlation with Ki-67 and p53 immunoreactivity. Gynecologic Oncology, 95(1), 23–31. https://doi.org/10.1016/j.ygyno.2004.06.046CrossRefPubMed

47.

Anttila, M., Kosma, V. M., Ji, H., Wei-Ling, X., Puolakka, J., Juhola, M., … Syrjänen, K. (1998). Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16(8), 2591–2600. https://doi.org/10.1200/JCO.1998.16.8.2591

48.

Yang, W.-L., Godwin, A. K., & Xu, X.-X. (2004). Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: Molecular basis linking ovulation and cancer risk. Cancer Research, 64(4), 1534–1540. https://doi.org/10.1158/0008-5472.can-03-2928CrossRefPubMed

49.

Brown, C. W., Brodsky, A. S., & Freiman, R. N. (2015). Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2. Molecular Cancer Research: MCR, 13(1), 78–85. https://doi.org/10.1158/1541-7786.MCR-14-0334CrossRefPubMed

50.

Uno, K., Iyoshi, S., Yoshihara, M., Kitami, K., Mogi, K., Fujimoto, H., … Kajiyama, H. (2022). Metastatic voyage of ovarian cancer cells in ascites with the assistance of various cellular components. International Journal of Molecular Sciences, 23(8), 4383. https://doi.org/10.3390/ijms23084383

51.

Chen, P., Cescon, M., & Bonaldo, P. (2013). Collagen VI in cancer and its biological mechanisms. Trends in Molecular Medicine, 19(7), 410–417. https://doi.org/10.1016/j.molmed.2013.04.001CrossRefPubMed

52.

Ho, C.-M., Chang, T.-H., Yen, T.-L., Hong, K.-J., & Huang, S.-H. (2021). Collagen type VI regulates the CDK4/6-p-Rb signaling pathway and promotes ovarian cancer invasiveness, stemness, and metastasis. American Journal of Cancer Research, 11(3), 668–690. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/33791147. Accessed 22 Aug 2023

53.

Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., … Morin, P. J. (2003). Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 3(4), 377–386. https://doi.org/10.1016/s1535-6108(03)00058-8

54.

Pietilä, E. A., Gonzalez-Molina, J., Moyano-Galceran, L., Jamalzadeh, S., Zhang, K., Lehtinen, L., … Lehti, K. (2021). Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nature Communications, 12(1), 3904. https://doi.org/10.1038/s41467-021-24009-8

55.

Nallanthighal, S., Rada, M., Heiserman, J. P., Cha, J., Sage, J., Zhou, B., … Cheon, D.-J. (2020). Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death & Disease, 11(4), 258. https://doi.org/10.1038/s41419-020-2442-z

56.

Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., … Orsulic, S. (2014). A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20(3), 711–723. https://doi.org/10.1158/1078-0432.CCR-13-1256

57.

Wu, Y.-H., Huang, Y.-F., Chang, T.-H., & Chou, C.-Y. (2017). Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF‐κB‐mediated IKKβ expression. International journal of cancer. Journal International du Cancer, 141(11), 2305–2317. https://doi.org/10.1002/ijc.30932

58.

Li, S.-L., Ye, F., Cai, W.-J., Hu, H.-D., Hu, P., Ren, H., … Zhang, D.-Z. (2010). Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. Journal of Cellular Biochemistry, 109(4), 625–633. https://doi.org/10.1002/jcb.22413

59.

Hata, K., Fujiwaki, R., Nakayama, K., & Miyazaki, K. (2001). Expression of the Endostatin gene in epithelial ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 7(8), 2405–2409. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11489819. Accessed 22 Aug 2023

60.

Gant, K. L., Jambor, A. N., Li, Z., Rentchler, E. C., Weisman, P., Li, L., … Campagnola, P. J. (2021). Evaluation of collagen alterations in early precursor lesions of high grade serous ovarian cancer by Second Harmonic Generation microscopy and mass spectrometry. Cancers, 13(11), 2794. https://doi.org/10.3390/cancers13112794

61.

Jiang, Y., Zhang, H., Wang, J., Liu, Y., Luo, T., & Hua, H. (2022). Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. Journal of Hematology & Oncology, 15(1), 34. https://doi.org/10.1186/s13045-022-01252-0CrossRef

62.

Kalli, M., & Stylianopoulos, T. (2018). Defining the role of solid stress and matrix stiffness in cancer cell proliferation and metastasis. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00055

63.

Fan, Y., Sun, Q., Li, X., Feng, J., Ao, Z., Li, X., & Wang, J. (2021). Substrate stiffness modulates the growth, phenotype, and chemoresistance of ovarian cancer cells. Frontiers in Cell and Developmental Biology, 9, 718834. https://doi.org/10.3389/fcell.2021.718834CrossRefPubMedPubMedCentral

64.

Mieulet, V., Garnier, C., Kieffer, Y., Guilbert, T., Nemati, F., Marangoni, E., … Mechta-Grigoriou, F. (2021). Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Scientific Reports, 11(1), 4219. https://doi.org/10.1038/s41598-021-83685-0

65.

Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., … Piccolo, S. (2011). Role of YAP/TAZ in mechanotransduction. Nature, 474(7350), 179–183. https://doi.org/10.1038/nature10137

66.

Hall, C. A., Wang, R., Miao, J., Oliva, E., Shen, X., Wheeler, T., … Goode, S. (2010). Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Research, 70(21), 8517–8525. https://doi.org/10.1158/0008-5472.CAN-10-1242

67.

Chen, G., Xie, J., Huang, P., & Yang, Z. (2016). Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer. Oncology Letters, 12(3), 1821–1825. https://doi.org/10.3892/ol.2016.4829CrossRefPubMedPubMedCentral

68.

McKenzie, A. J., Hicks, S. R., Svec, K. V., Naughton, H., Edmunds, Z. L., & Howe, A. K. (2018). The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-25589-0

69.

McKenzie, A. J., Hicks, S. R., Svec, K. V., Naughton, H., Edmunds, Z. L., & Howe, A. K. (2017, December 21). The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. bioRxiv. bioRxiv. https://doi.org/10.1101/238311

70.

Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., … Sahai, E. (2013). Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature Cell Biology, 15(6), 637–646. https://doi.org/10.1038/ncb2756

71.

Xia, Y., Chang, T., Wang, Y., Liu, Y., Li, W., Li, M., & Fan, H.-Y. (2014). YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS ONE, 9(3), e91770. https://doi.org/10.1371/journal.pone.0091770CrossRefPubMedPubMedCentral

72.

Wei, X., Lou, H., Zhou, D., Jia, Y., Li, H., Huang, Q., … Gao, Q. (2021). TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA/ROCK pathway. Journal of Experimental & Clinical Cancer Research: CR, 40(1), 292. https://doi.org/10.1186/s13046-021-02091-6

73.

Chang, J., Pang, E. M., Adebowale, K., Wisdom, K. M., & Chaudhuri, O. (2020). Increased stiffness inhibits invadopodia formation and cell migration in 3D. Biophysical Journal, 119(4), 726–736. https://doi.org/10.1016/j.bpj.2020.07.003CrossRefPubMedPubMedCentral

74.

Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., … Rankin, E. B. (2019). Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Research, 79(9), 2271–2284. https://doi.org/10.1158/0008-5472.can-18-2616

75.

Malik, R., Lelkes, P. I., & Cukierman, E. (2015). Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends in Biotechnology, 33(4), 230–236. https://doi.org/10.1016/j.tibtech.2015.01.004CrossRefPubMedPubMedCentral

76.

Cox, T. R., & Erler, J. T. (2011). Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Disease Models & Mechanisms, 4(2), 165–178. https://doi.org/10.1242/dmm.004077CrossRef

77.

Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006). Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Medicine, 4(1), 38. https://doi.org/10.1186/1741-7015-4-38CrossRefPubMedPubMedCentral

78.

Brett, E. A., Sauter, M. A., Machens, H.-G., & Duscher, D. (2020). Tumor-associated collagen signatures: Pushing tumor boundaries. Cancer & Metabolism, 8(1), 14. https://doi.org/10.1186/s40170-020-00221-wCrossRef

79.

Han, W., Chen, S., Yuan, W., Fan, Q., Tian, J., Wang, X., … Liu, L. (2016). Oriented collagen fibers direct tumor cell intravasation. Proceedings of the National Academy of Sciences of the United States of America, 113(40), 11208–11213. https://doi.org/10.1073/pnas.1610347113

80.

Ray, A., Slama, Z. M., Morford, R. K., Madden, S. A., & Provenzano, P. P. (2017). Enhanced directional migration of cancer stem cells in 3D aligned collagen matrices. Biophysical Journal, 112(5), 1023–1036. https://doi.org/10.1016/j.bpj.2017.01.007CrossRefPubMedPubMedCentral

81.

Xi, G., Qiu, L., Xu, S., Guo, W., Fu, F., Kang, D., … Chen, J. (2021). Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer. BMC Medicine, 19(1), 273. https://doi.org/10.1186/s12916-021-02146-7

82.

Conklin, M. W., Eickhoff, J. C., Riching, K. M., Pehlke, C. A., Eliceiri, K. W., Provenzano, P. P., … Keely, P. J. (2011). Aligned collagen is a prognostic signature for survival in human breast carcinoma. The American Journal of Pathology, 178(3), 1221–1232. https://doi.org/10.1016/j.ajpath.2010.11.076

83.

Campbell, K. R., Chaudhary, R., Handel, J. M., Patankar, M. S., & Campagnola, P. J. (2018). Polarization-resolved second harmonic generation imaging of human ovarian cancer. Journal of Biomedical Optics, 23(6), 1–8. https://doi.org/10.1117/1.JBO.23.6.066501CrossRefPubMed

84.

Tilbury, K. B., Campbell, K. R., Eliceiri, K. W., Salih, S. M., Patankar, M., & Campagnola, P. J. (2017). Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering. BMC Cancer, 17(1). https://doi.org/10.1186/s12885-017-3090-2

85.

Wen, B., Campbell, K. R., Tilbury, K., Nadiarnykh, O., Brewer, M. A., Patankar, M., … Campagnola, P. J. (2016). 3D texture analysis for classification of second harmonic generation images of human ovarian cancer. Scientific Reports, 6, 35734. https://doi.org/10.1038/srep35734

86.

Yan, J., Zhao, Y., Lin, F., Qu, J., Liu, Q., Pan, Y., & Liu, L. (2021). Monitoring the extracellular matrix remodeling of high-grade serous ovarian cancer with nonlinear optical microscopy. Journal of Biophotonics, 14(6), e202000498. https://doi.org/10.1002/jbio.202000498CrossRefPubMed

87.

Alkmin, S., Brodziski, R., Simon, H., Hinton, D., Goldsmith, R. H., Patankar, M., & Campagnola, P. J. (2020). Role of collagen fiber morphology on ovarian cancer cell migration using image-based models of the extracellular matrix. Cancers, 12(6), 1390. https://doi.org/10.3390/cancers12061390CrossRefPubMedPubMedCentral

88.

Sneider, A., Kiemen, A., Kim, J. H., Wu, P.-H., Habibi, M., White, M., … Wirtz, D. (2022). Deep learning identification of stiffness markers in breast cancer. Biomaterials, 285(121540), 121540. https://doi.org/10.1016/j.biomaterials.2022.121540

89.

Jia, H., Janjanam, J., Wu, S. C., Wang, R., Pano, G., Celestine, M., … Labelle, M. (2019). The tumor cell-secreted matricellular protein WISP1 drives pro-metastatic collagen linearization. The EMBO Journal, 38(16), e101302. https://doi.org/10.15252/embj.2018101302

90.

Li, Y., Wang, F., Liu, T., Lv, N., Yuan, X., & Li, P. (2022). WISP1 induces ovarian cancer via the IGF1/αvβ3/Wnt axis. Journal of Ovarian Research, 15(1). https://doi.org/10.1186/s13048-022-01016-x

91.

Wilkosz, S., Ireland, G., Khwaja, N., Walker, M., Butt, R., de Giorgio-Miller, A., & Herrick, S. E. (2005). A comparative study of the structure of human and murine greater omentum. Anatomy and Embryology, 209(3), 251–261. https://doi.org/10.1007/s00429-004-0446-6CrossRefPubMed

92.

Simer, P. H. (1944). The drainage of particulate matter from the peritoneal cavity by lymphatics. The Anatomical Record, 88(2), 175–192. https://doi.org/10.1002/ar.1090880205CrossRef

93.

Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., … Lengyel, E. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 17(11), 1498–1503. https://doi.org/10.1038/nm.2492

94.

Meza-Perez, S., & Randall, T. D. (2017). Immunological functions of the omentum. Trends in Immunology, 38(7), 526–536. https://doi.org/10.1016/j.it.2017.03.002CrossRefPubMedPubMedCentral

95.

Ma, X. (2020, April 6). The omentum, a niche for premetastatic ovarian cancer. The journal of experimental medicine. Rockefeller University Press. https://doi.org/10.1084/jem.20192312

96.

Etzerodt, A., Moulin, M., Doktor, T. K., Delfini, M., Mossadegh-Keller, N., Bajenoff, M., … Lawrence, T. (2020). Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. The Journal of Experimental Medicine, 217(4). https://doi.org/10.1084/jem.20191869

97.

Di Nicola, V. (2019). Omentum a powerful biological source in regenerative surgery. Regenerative Therapy, 11, 182–191. https://doi.org/10.1016/j.reth.2019.07.008CrossRefPubMedPubMedCentral

98.

Chin, A. R., & Wang, S. E. (2016). Cancer tills the premetastatic field: Mechanistic basis and clinical implications. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22(15), 3725–3733. https://doi.org/10.1158/1078-0432.CCR-16-0028CrossRefPubMed

99.

Mogi, K., Yoshihara, M., Iyoshi, S., Kitami, K., Uno, K., Tano, S., … Kajiyama, H. (2021). Ovarian cancer-associated mesothelial cells: Transdifferentiation to minions of cancer and orchestrate developing peritoneal dissemination. Cancers, 13(6), 1352. https://doi.org/10.3390/cancers13061352

100.

Kenny, H. A., Dogan, S., Zillhardt, M., Mitra, A. K., Yamada, S. D., Krausz, T., & Lengyel, E. (2009). Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treatment and Research, 149, 335–351. https://doi.org/10.1007/978-0-387-98094-2_16CrossRefPubMedPubMedCentral

101.

Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., … Rizvi, I. (2021). Malignant ascites in ovarian cancer: Cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers, 13(17), 4318. https://doi.org/10.3390/cancers13174318

102.

Santin, A. D., Bellone, S., Ravaggi, A., Roman, J., Smith, C. V., Pecorelli, S., … Parham, G. P. (2001). Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer. British Journal of Obstetrics and Gynaecology, 108(8), 804–808. https://doi.org/10.1016/s0306-5456(00)00206-0

103.

Drabsch, Y., & ten Dijke, P. (2012). TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Reviews, 31(3–4), 553–568. https://doi.org/10.1007/s10555-012-9375-7CrossRefPubMed

104.

Pickup, M., Novitskiy, S., & Moses, H. L. (2013). The roles of TGFβ in the tumour microenvironment. Nature Reviews. Cancer, 13(11), 788–799. https://doi.org/10.1038/nrc3603CrossRefPubMedPubMedCentral

105.

Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021). TGFβ signaling networks in ovarian cancer progression and plasticity. Clinical & Experimental Metastasis, 38(2), 139–161. https://doi.org/10.1007/s10585-021-10077-zCrossRef

106.

Kenny, H. A., Chiang, C.-Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L., … Lengyel, E. (2014). Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of Clinical Investigation, 124(10), 4614–4628. https://doi.org/10.1172/jci74778

107.

Sugiyama, K., Kajiyama, H., Shibata, K., Yuan, H., Kikkawa, F., & Senga, T. (2014). Expression of the miR200 family of microRNAs in mesothelial cells suppresses the dissemination of ovarian cancer cells. Molecular Cancer Therapeutics, 13(8), 2081–2091. https://doi.org/10.1158/1535-7163.mct-14-0135CrossRefPubMed

108.

Kajiyama, H., Shibata, K., Ino, K., Nawa, A., Mizutani, S., & Kikkawa, F. (2007). Possible involvement of SDF-1alpha/CXCR4-DPPIV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells. Cell and Tissue Research, 330(2), 221–229. https://doi.org/10.1007/s00441-007-0455-xCrossRefPubMed

109.

Kajiyama, H., Shibata, K., Terauchi, M., Ino, K., Nawa, A., & Kikkawa, F. (2008). Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. International journal of cancer. Journal International du Cancer, 122(1), 91–99. https://doi.org/10.1002/ijc.23083

110.

Cai, J., Tang, H., Xu, L., Wang, X., Yang, C., Ruan, S., … Wang, Z. (2012). Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis, 33(1), 20–29. https://doi.org/10.1093/carcin/bgr230

111.

Tang, H., Chu, Y., Huang, Z., Cai, J., & Wang, Z. (2020). The metastatic phenotype shift toward myofibroblast of adipose-derived mesenchymal stem cells promotes ovarian cancer progression. Carcinogenesis, 41(2), 182–193. https://doi.org/10.1093/carcin/bgz083CrossRefPubMed

112.

Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., … Ahmed, A. A. (2019). An evolving story of the metastatic voyage of ovarian cancer cells: Cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene, 38(16), 2885–2898. https://doi.org/10.1038/s41388-018-0637-x

113.

Zhang, Y., Tang, H., Cai, J., Zhang, T., Guo, J., Feng, D., & Wang, Z. (2011). Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Letters, 303(1), 47–55. https://doi.org/10.1016/j.canlet.2011.01.011CrossRefPubMed

114.

Nakamura, K., Sawada, K., Kobayashi, M., Miyamoto, M., Shimizu, A., Yamamoto, M., … Kimura, T. (2019). Role of the exosome in ovarian cancer progression and its potential as a therapeutic target. Cancers, 11(8), 1147. https://doi.org/10.3390/cancers11081147

115.

Feng, W., Dean, D. C., Hornicek, F. J., Shi, H., & Duan, Z. (2019). Exosomes promote pre-metastatic niche formation in ovarian cancer. Molecular Cancer, 18(1), 124. https://doi.org/10.1186/s12943-019-1049-4CrossRefPubMedPubMedCentral

116.

Cho, J. A., Park, H., Lim, E. H., Kim, K. H., Choi, J. S., Lee, J. H., … Lee, K. W. (2011). Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecologic Oncology, 123(2), 379–386. https://doi.org/10.1016/j.ygyno.2011.08.005

117.

Giusti, I., Francesco, M. D., Ascenzo, S. D., Palmerini, M. G., Macchiarelli, G., Carta, G., & Dolo, V. (2018). Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior. Cancer Biology & Therapy, 1–44. https://doi.org/10.1080/15384047.2018.1451286

118.

Lee, A. H., Ghosh, D., Quach, N., Schroeder, D., & Dawson, M. R. (2020). Ovarian cancer exosomes trigger differential biophysical response in tumor-derived fibroblasts. Scientific Reports, 10(1), 8686. https://doi.org/10.1038/s41598-020-65628-3CrossRefPubMedPubMedCentral

119.

Han, Q., Tan, S., Gong, L., Li, G., Wu, Q., Chen, L., … Wang, Z. (2023). Omental cancer‐associated fibroblast‐derived exosomes with low microRNA‐29c‐3p promote ovarian cancer peritoneal metastasis. Cancer Rcience, 114(5), 1929–1942. https://doi.org/10.1111/cas.15726

120.

Zhu, Y., Wang, C., Ma, Z., Li, F., Xu, C., Pan, W., & Liu, A. (2023). Role of exosomes in the invasion and metastasis of ovarian cancer and application potential of clinical diagnosis and treatment. Journal of Cancer, 14(7), 1141–1150. https://doi.org/10.7150/jca.83663CrossRefPubMedPubMedCentral

121.

Lee, W., Ko, S. Y., Mohamed, M. S., Kenny, H. A., Lengyel, E., & Naora, H. (2019). Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. The Journal of Experimental Medicine, 216(1), 176–194. https://doi.org/10.1084/jem.20181170CrossRefPubMedPubMedCentral

122.

Yoshihara, M., Kajiyama, H., Yokoi, A., Sugiyama, M., Koya, Y., Yamakita, Y., … Kikkawa, F. (2020). Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway. International Journal of Cancer. Journal International du Cancer, 146(8), 2268–2280. https://doi.org/10.1002/ijc.32854

123.

Li, W., Zhang, X., Wang, J., Li, M., Cao, C., Tan, J., … Gao, Q. (2017). TGFβ1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget, 8(56), 96035–96047. https://doi.org/10.18632/oncotarget.21635

124.

Vergara, D., Merlot, B., Lucot, J.-P., Collinet, P., Vinatier, D., Fournier, I., & Salzet, M. (2010). Epithelial-mesenchymal transition in ovarian cancer. Cancer letters, 291(1), 59–66. https://doi.org/10.1016/j.canlet.2009.09.017CrossRefPubMed

125.

Huang, Y.-L., Liang, C.-Y., Ritz, D., Coelho, R., Septiadi, D., Estermann, M., … Heinzelmann-Schwarz, V. (2020). Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis. eLife, 9. https://doi.org/10.7554/eLife.59442

126.

Gertych, A., Walts, A. E., Cheng, K., Liu, M., John, J., Lester, J., … Orsulic, S. (2022). Dynamic changes in the extracellular matrix in primary, metastatic, and recurrent ovarian cancers. Cells (Basel, Switzerland), 11(23), 3769. https://doi.org/10.3390/cells11233769

127.

Loizzi, V., Del Vecchio, V., Gargano, G., De Liso, M., Kardashi, A., Naglieri, E., … Cormio, G. (2017). Biological pathways involved in tumor angiogenesis and bevacizumab based anti-angiogenic therapy with special references to ovarian cancer. International Journal of Molecular Sciences, 18(9), 1967. https://doi.org/10.3390/ijms18091967

128.

Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., … Jain, R. K. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nature communications, 4, 2516. https://doi.org/10.1038/ncomms3516

129.

Wang, X., Du, Z.-W., Xu, T.-M., Wang, X.-J., Li, W., Gao, J.-L., … Zhu, H. (2021). HIF-1α is a rational target for future ovarian cancer therapies. Frontiers in Oncology, 11, 785111. https://doi.org/10.3389/fonc.2021.785111

130.

Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018). The hypoxic tumour microenvironment. Oncogenesis, 7(1), 10. https://doi.org/10.1038/s41389-017-0011-9CrossRefPubMedPubMedCentral

131.

Wei, R., Lv, M., Li, F., Cheng, T., Zhang, Z., Jiang, G., … Xi, L. (2017). Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Oncotarget, 8(40), 67315–67328. https://doi.org/10.18632/oncotarget.18621

132.

Leong, S. P., Naxerova, K., Keller, L., Pantel, K., & Witte, M. (2022). Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clinical & Experimental Metastasis, 39(1), 159–179. https://doi.org/10.1007/s10585-021-10120-zCrossRef

133.

Morry, J., Ngamcherdtrakul, W., & Yantasee, W. (2017). Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biology, 11, 240–253. https://doi.org/10.1016/j.redox.2016.12.011CrossRefPubMed

134.

Ding, D.-N., Xie, L.-Z., Shen, Y., Li, J., Guo, Y., Fu, Y., … Han, F.-J. (2021). Insights into the role of oxidative stress in ovarian cancer. Oxidative Medicine and Cellular Longevity, 2021, 1–20. https://doi.org/10.1155/2021/8388258

135.

Liu, W.-J., Huang, Y.-X., Wang, W., Zhang, Y., Liu, B.-J., Qiu, J.-G., … Liu, L.-Z. (2021). NOX4 signaling mediates cancer development and therapeutic resistance through HER3 in ovarian cancer cells. Cells (Basel, Switzerland), 10(7), 1647. https://doi.org/10.3390/cells10071647

136.

Hu, Y., Taylor-Harding, B., Raz, Y., Haro, M., Recouvreux, M. S., Taylan, E., … Orsulic, S. (2020). Are epithelial ovarian cancers of the mesenchymal subtype actually intraperitoneal metastases to the ovary? Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.00647

137.

Winter, W. E., 3rd, Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., … Gynecologic Oncology Group Study. (2007). Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25(24), 3621–3627. https://doi.org/10.1200/JCO.2006.10.2517

138.

Mikuła-Pietrasik, J., Witucka, A., Pakuła, M., Uruski, P., Begier-Krasińska, B., Niklas, A., … Książek, K. (2019). Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. Cellular and molecular life sciences: CMLS, 76(4), 681–697. https://doi.org/10.1007/s00018-018-2954-1

139.

Yeldag, G., Rice, A., & Del Río Hernández, A. (2018). Chemoresistance and the self-maintaining tumor microenvironment. Cancers, 10(12), 471. https://doi.org/10.3390/cancers10120471CrossRefPubMedPubMedCentral

140.

Zheng, H.-C. (2017). The molecular mechanisms of chemoresistance in cancers. Oncotarget, 8(35), 59950–59964. https://doi.org/10.18632/oncotarget.19048

141.

Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021). Ovarian cancer immunotherapy and personalized medicine. International Journal of Molecular Sciences, 22(12), 6532. https://doi.org/10.3390/ijms22126532CrossRefPubMedPubMedCentral

142.

Kuroki, L., & Guntupalli, S. R. (2020). Treatment of epithelial ovarian cancer. BMJ (Clinical Research ed.), 371, m3773. https://doi.org/10.1136/bmj.m3773CrossRefPubMed

143.

Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018). Targeting the tumour stroma to improve cancer therapy. Nature Reviews. Clinical Oncology, 15(6), 366–381. https://doi.org/10.1038/s41571-018-0007-1CrossRefPubMedPubMedCentral

144.

Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., … Xu, L. (2019). Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 116(6), 2210–2219. https://doi.org/10.1073/pnas.1818357116

145.

Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., … Jain, R. K. (2012). Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proceedings of the National Academy of Sciences of the United States of America, 109(38), 15101–15108. https://doi.org/10.1073/pnas.1213353109

146.

Ko, S. Y., & Naora, H. (2014). Therapeutic strategies for targeting the ovarian tumor stroma. World Journal of Clinical Cases, 2(6), 194–200. https://doi.org/10.12998/wjcc.v2.i6.194

147.

Chien, J., Kuang, R., Landen, C., & Shridhar, V. (2013). Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment. Frontiers in Oncology, 3, 251. https://doi.org/10.3389/fonc.2013.00251CrossRefPubMedPubMedCentral

148.

Tatsuki, S., Shoji, T., Abe, M., Tomabechi, H., Takatori, E., Kaido, Y., … Baba, T. (2022). Efficacy and safety of platinum rechallenge in patients with platinum-resistant ovarian, Fallopian tube or primary peritoneal cancer: A multicenter retrospective study. Anticancer Research, 42(9), 4603–4610. https://doi.org/10.21873/anticanres.15964

149.

Melssen, M. M., Sheybani, N. D., Leick, K. M., & Slingluff, C. L., Jr. (2023). Barriers to immune cell infiltration in tumors. Journal for Immunotherapy of Cancer, 11(4), e006401. https://doi.org/10.1136/jitc-2022-006401CrossRefPubMedPubMedCentral

150.

Nicolas-Boluda, A., Vaquero, J., Vimeux, L., Guilbert, T., Barrin, S., Kantari-Mimoun, C., … Donnadieu, E. (2021). Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife, 10. https://doi.org/10.7554/eLife.58688

151.

Mancini, M. L., & Sonis, S. T. (2014). Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Frontiers in Pharmacology, 5, 51. https://doi.org/10.3389/fphar.2014.00051CrossRefPubMedPubMedCentral

152.

Hynninen, J., Lavonius, M., Oksa, S., Grénman, S., Carpén, O., & Auranen, A. (2013). Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecologic Oncology, 128(2), 229–232. https://doi.org/10.1016/j.ygyno.2012.11.007CrossRefPubMed

153.

Samrao, D., Wang, D., Ough, F., Lin, Y. G., Liu, S., Menesses, T., … Mhawech-Fauceglia, P. (2012). Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Translational Oncology, 5(6), 469–474. https://doi.org/10.1593/tlo.12265

154.

Kaukonen, R., Mai, A., Georgiadou, M., Saari, M., De Franceschi, N., Betz, T., … Ivaska, J. (2016). Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nature Communications, 7(1), 12237. https://doi.org/10.1038/ncomms12237

155.

Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022). Targeting the tumor stroma for cancer therapy. Molecular Cancer, 21(1), 208. https://doi.org/10.1186/s12943-022-01670-1CrossRefPubMedPubMedCentral

156.

Hofmeister, V., Schrama, D., & Becker, J. C. (2008). Anti-cancer therapies targeting the tumor stroma. Cancer Immunology, Immunotherapy: CII, 57(1), 1–17. https://doi.org/10.1007/s00262-007-0365-5CrossRefPubMed

157.

Heindryckx, F., & Gerwins, P. (2015). Targeting the tumor stroma in hepatocellular carcinoma. World Journal of Hepatology, 7(2), 165–176. https://doi.org/10.4254/wjh.v7.i2.165CrossRefPubMedPubMedCentral

158.

Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J., & Provenzano, P. P. (2019). Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Research, 79(2), 372–386. https://doi.org/10.1158/0008-5472.CAN-18-1334CrossRefPubMed

159.

Neesse, A., Krug, S., Gress, T. M., Tuveson, D. A., & Michl, P. (2013). Emerging concepts in pancreatic cancer medicine: Targeting the tumor stroma. OncoTargets and Therapy, 7, 33–43. https://doi.org/10.2147/OTT.S38111CrossRefPubMedPubMedCentral

160.

Hutchenreuther, J., & Leask, A. (2018). Why target the tumor stroma in melanoma? Journal of Cell Communication and Signaling, 12(1), 113–118. https://doi.org/10.1007/s12079-017-0419-1CrossRefPubMed

161.

Wynn, T. A. (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. The Journal of Clinical Investigation, 117(3), 524–529. https://doi.org/10.1172/JCI31487CrossRefPubMedPubMedCentral

162.

Suganuma, T., Ino, K., Shibata, K., Kajiyama, H., Nagasaka, T., Mizutani, S., & Kikkawa, F. (2005). Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11(7), 2686–2694. https://doi.org/10.1158/1078-0432.CCR-04-1946CrossRefPubMed

163.

McCloskey, C. W., Cook, D. P., Kelly, B. S., Azzi, F., Allen, C. H., Forsyth, A., … Vanderhyden, B. C. (2020, February 1). Metformin abrogates age-associated ovarian fibrosis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. American Association for Cancer Research (AACR). https://doi.org/10.1158/1078-0432.CCR-19-0603

164.

Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ (Clinical Research ed.), 330(7503), 1304–1305. https://doi.org/10.1136/bmj.38415.708634.F7CrossRefPubMed

165.

Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016). Metformin as an adjuvant treatment for cancer: A systematic review and meta-analysis. Annals of Oncology, 27(12), 2184–2195. https://doi.org/10.1093/annonc/mdw410CrossRefPubMedPubMedCentral

166.

Urpilainen, E., Puistola, U., Boussios, S., & Karihtala, P. (2020). Metformin and ovarian cancer: The evidence. Annals of Translational Medicine, 8(24), 1711. https://doi.org/10.21037/atm-20-1060

167.

Guglielmi, V., Cardellini, M., Cinti, F., Corgosinho, F., Cardolini, I., D’Adamo, M., … Sbraccia, P. (2015). Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutrition & Diabetes, 5(8), e175. https://doi.org/10.1038/nutd.2015.22

168.

Saini, N., & Yang, X. (2018). Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta biochimica et biophysica Sinica, 50(2), 133–143. https://doi.org/10.1093/abbs/gmx106CrossRefPubMed

169.

Fielding, C. A., Jones, G. W., McLoughlin, R. M., McLeod, L., Hammond, V. J., Uceda, J., … Jones, S. A. (2014). Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity, 40(1), 40–50. https://doi.org/10.1016/j.immuni.2013.10.022

170.

Yang, X., Huang, M., Zhang, Q., Chen, J., Li, J., Han, Q., … Han, B. (2021). Metformin antagonizes ovarian cancer cells malignancy through MSLN mediated IL-6/STAT3 signaling. Cell Transplantation, 30, 9636897211027820. https://doi.org/10.1177/09636897211027819

171.

Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., … Buckanovich, R. J. (2020). Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight, 5(11). https://doi.org/10.1172/jci.insight.133247

172.

Thorlacius-Ussing, J., Jensen, C., Madsen, E. A., Nissen, N. I., Manon-Jensen, T., Chen, I. M., Johansen, J. S., Diab, H. M. H., Jørgensen, L. N., Karsdal, M. A., & Willumsen, N. (2022). Type XX collagen is elevated in circulation of patients with solid tumors. International Journal of Molecular Sciences, 23(8), 4144. https://doi.org/10.3390/ijms23084144CrossRefPubMedPubMedCentral

At a glance: The STEP trials

Springer Medicine

Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer